Construction of Capsid-Modified Adenoviruses by Recombination in Yeast and Purification by Iodixanol-Gradient

  • Marta Giménez-Alejandre
  • Alena Gros
  • Ramón Alemany
Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 797)

Abstract

Adenovirus represents a valuable tool for the treatment of cancer, but tumor targeting remains a pending issue. Most common procedures to modify adenovirus genome are time-consuming due to the requirement of multiple cloning steps, and the low efficacy of the recombination process. Here, we present a new method for homologous recombination in yeast to fast construct recombinant adenoviruses. Also, an alternative procedure to purify viral stocks, based on iodixanol gradient is described. Compared to classical methods, iodixanol is nontoxic to cells, which avoids desalting to use in vitro and in vivo. Moreover, viral stocks are more viable and it can be used for large-scale purifications. Finally, a protocol for analyzing blood persistence of modified vector in in vivo biodistribution is presented.

Key words

Adenovirus Detargeting Homologous recombination Iodixanol Biodistribution 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We thank to Manel Cascalló and Lynda Coughlan for critical ­reading of the manuscript.

References

  1. 1.
    Alemany, R., and Curiel, D. T. (2001) CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors, Gene therapy 8, 1347–1353.Google Scholar
  2. 2.
    Bayo-Puxan, N., Cascallo, M., Gros, A., Huch, M., Fillat, C., and Alemany, R. (2006) Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting, The Journal of general virology 87, 2487–2495.Google Scholar
  3. 3.
    Einfeld, D. A., Schroeder, R., Roelvink, P. W., Lizonova, A., King, C. R., Kovesdi, I., and Wickham, T. J. (2001) Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions, Journal of virology 75, 11284–11291.Google Scholar
  4. 4.
    Smith, T. A., Idamakanti, N., Rollence, M. L., Marshall-Neff, J., Kim, J., Mulgrew, K., Nemerow, G. R., Kaleko, M., and Stevenson, S. C. (2003) Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice, Human gene therapy 14, 777–787.Google Scholar
  5. 5.
    Kritz, A. B., Nicol, C. G., Dishart, K. L., Nelson, R., Holbeck, S., Von Seggern, D. J., Work, L. M., McVey, J. H., Nicklin, S. A., and Baker, A. H. (2007) Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop, Mol Ther 15, 741–749.Google Scholar
  6. 6.
    Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z. Y., and Lieber, A. (2005) Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity, Journal of virology 79, 7478–7491.Google Scholar
  7. 7.
    Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Hofherr, S. E., Barry, M. A., Stewart, P. L., and Shayakhmetov, D. M. (2008) Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo, Proceedings of the National Academy of Sciences of the United States of America 105, 5483–5488.Google Scholar
  8. 8.
    Waddington SN, M. J., Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer., Cell 132, 397–409.Google Scholar
  9. 9.
    Alba, R., Bradshaw, A. C., Parker, A. L., Bhella, D., Waddington, S. N., Nicklin, S. A., van Rooijen, N., Custers, J., Goudsmit, J., Barouch, D. H., McVey, J. H., and Baker, A. H. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer, Blood 114, 965–971.Google Scholar
  10. 10.
    Carlisle, R. C., Di, Y., Cerny, A. M., Sonnen, A. F., Sim, R. B., Green, N. K., Subr, V., Ulbrich, K., Gilbert, R. J., Fisher, K. D., Finberg, R. W., and Seymour, L. W. (2009) Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1, Blood 113, 1909–1918.Google Scholar
  11. 11.
    Stone, D., Liu, Y., Shayakhmetov, D., Li, Z. Y., Ni, S., and Lieber, A. (2007) Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver, Journal of virology 81, 4866–4871.Google Scholar
  12. 12.
    Morrison, J., Briggs, S. S., Green, N., Fisher, K., Subr, V., Ulbrich, K., Kehoe, S., and Seymour, L. W. (2008) Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor, Mol Ther 16, 244–251.Google Scholar
  13. 13.
    Korn, T., Nettelbeck, D. M., Volkel, T., Muller, R., and Kontermann, R. E. (2004) Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv, The journal of gene medicine 6, 642–651.Google Scholar
  14. 14.
    Dmitriev, I., Kashentseva, E., Rogers, B. E., Krasnykh, V., and Curiel, D. T. (2000) Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells, Journal of virology 74, 6875–6884.Google Scholar
  15. 15.
    Bayo-Puxan, N., Gimenez-Alejandre, M., Lavilla-Alonso, S., Gros, A., Cascallo, M., Hemminki, A., and Alemany, R. (2009) Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting, Human gene therapy 20, 1214–1221.Google Scholar
  16. 16.
    Magnusson, M. K., Henning, P., Myhre, S., Wikman, M., Uil, T. G., Friedman, M., Andersson, K. M., Hong, S. S., Hoeben, R. C., Habib, N. A., Stahl, S., Boulanger, P., and Lindholm, L. (2007) Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu, Cancer gene therapy 14, 468–479.Google Scholar
  17. 17.
    Coughlan, L., Vallath, S., Saha, A., Flak, M., McNeish, I. A., Vassaux, G., Marshall, J. F., Hart, I. R., and Thomas, G. J. (2009) In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery, Journal of virology 83, 6416–6428.Google Scholar
  18. 18.
    He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. (1998) A simplified system for generating recombinant adenoviruses, Proceedings of the National Academy of Sciences of the United States of America 95, 2509–2514.Google Scholar
  19. 19.
    Hokanson, C. A., Dora, E., Donahue, B. A., Rivkin, M., Finer, M., and Mendez, M. J. (2003) Hybrid yeast-bacteria cloning system used to capture and modify adenoviral and nonviral genomes, Hum Gene Ther 14, 329–339.Google Scholar
  20. 20.
    Gietz, R. D., and Woods, R. A. (2002) Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method, Methods in enzymology 350, 87–96.Google Scholar
  21. 21.
    Gietz, R. D., and Woods, R. A. (2006) Yeast transformation by the LiAc/SS Carrier DNA/PEG method, Methods in molecular biology (Clifton, N.J) 313, 107–120.Google Scholar
  22. 22.
    Peng, H. H., Wu, S., Davis, J. J., Wang, L., Roth, J. A., Marini, F. C., 3rd, and Fang, B. (2006) A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers, Analytical biochemistry 354, 140–147.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Marta Giménez-Alejandre
    • 1
  • Alena Gros
    • 2
  • Ramón Alemany
    • 3
  1. 1.Institut Català d’Oncologia – IDIBELLL’Hospitalet de LlobregatBarcelonaSpain
  2. 2.National Cancer InstituteUS National Institutes of HealthBethesdaUSA
  3. 3.Laboratori de Recerca Translacional, Institut Català d’Oncologia – IDIBELLL’Hospitalet de LlobregatBarcelonaSpain

Personalised recommendations